Trials / Completed
CompletedNCT00488514
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 656 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents for the acute treatment of migraine.
Detailed description
This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents (aged 12 to 17 years) for the acute treatment of migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combination Tablet of Treximet (sumatriptan/naproxen sodium) | Combination Tablet of Treximet(sumatriptan/naproxen sodium) |
Timeline
- Start date
- 2007-07-13
- Primary completion
- 2009-08-01
- Completion
- 2009-08-20
- First posted
- 2007-06-20
- Last updated
- 2017-05-18
- Results posted
- 2010-09-06
Locations
77 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00488514. Inclusion in this directory is not an endorsement.